The purpose of this study is to assess the safety and tolerability of single and multiple intravenous doses of SPR741 when administered to healthy adult volunteers.
This Phase 1 First in Human study is designed to assess the safety, tolerability and pharmacokinetics of single and multiple intravenous doses of SPR741 when administered to healthy adult volunteers. This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. A total of ninety-six healthy volunteers will be enrolled in 12 cohorts. The study will be conducted in two phases: a single ascending dose (SAD) phase, followed by a multiple ascending dose (MAD) phase. In SAD, participants will receive one dose of SPR741 or placebo. In MAD, participants will receive multiple doses of SPR741 or placebo for 14 consecutive days. In both parts, sequential cohorts will be exposed to increasing doses of SPR741.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
64
SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days.
0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
CMAX - A division of IDT Australia, Limited
Adelaide, South Australia, Australia
Safety measures: adverse events
The frequency and type of adverse events
Time frame: SAD: 5 to 7 days MAD: 21 to 23 days
Safety measures: clinical laboratory testing
Clinical laboratory testing - change from baseline to end of study visit
Time frame: SAD: Day -1 to day 7; MAD: Day -1 to day 21
Safety measures: pulse rate
Change from baseline to end of study visit
Time frame: SAD: Day -1 to day 7; MAD: Day -1 to day 21
Safety measures: EKG
Change from baseline to end of study visit
Time frame: SAD: 5 to 7 days MAD: 21 to 23 days
Safety measures: respiratory rate
Change from baseline to end of study visit
Time frame: SAD: Day -1 to day 7; MAD: Day -1 to day 21
Safety measures: blood pressure
Change from baseline to end of study visit
Time frame: SAD: Day -1 to day 7; MAD: Day -1 to day 21
Individual SPR741 plasma concentration-time curves will be tabulated for each dose cohort.
• Blood draws for PK: pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 90, 150 minutes, 3, 4, 5, 6 and 8 hours following start of infusion (Day 1 (first dose) and Day 14 (last dose)). Five additional blood draws will be obtained at 10, 12, 24, 36 and 48 hours following the start of infusion of the last dose (morning of Day 14).
Time frame: Day 1 and Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Geometric means will be calculated for Area Under the Curve (AUC)
Blood draws for PK: pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 90, 150 minutes, 3, 4, 5, 6 and 8 hours following start of infusion (Day 1 (first dose) and Day 14 (last dose)). Five additional blood draws will be obtained at 10, 12, 24, 36 and 48 hours following the start of infusion of the last dose (morning of Day 14).
Time frame: Day 1 and Day 14
Geometric means will be calculated for Concentration maximum (Cmax)
Blood draws for PK: pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 90, 150 minutes, 3, 4, 5, 6 and 8 hours following start of infusion (Day 1 (first dose) and Day 14 (last dose)). Five additional blood draws will be obtained at 10, 12, 24, 36 and 48 hours following the start of infusion of the last dose (morning of Day 14).
Time frame: Day 1 and Day 14
Geometric means will be calculated for Area Under the Curve (AUC) Urine
• Urine collection for PK: pre-dose Day 1 sample, total collection over 0-4, 4-8 hours following start of infusion of first dose on Day 1; then total collection over 0-4, 4-8, 8-12, 12-24 and 24-48 hours following start of infusion of the last dose (Day 14).
Time frame: Day 1 and Day 14
Geometric means will be calculated for Concentration maximum (Cmax) Urine
• Urine collection for PK: pre-dose Day 1 sample, total collection over 0-4, 4-8 hours following start of infusion of first dose on Day 1; then total collection over 0-4, 4-8, 8-12, 12-24 and 24-48 hours following start of infusion of the last dose (Day 14).
Time frame: Day 1 and Day 14
Mean SPR741 plasma concentration-time curves will be tabulated for each dose cohort.
• Blood draws for PK: pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 90, 150 minutes, 3, 4, 5, 6 and 8 hours following start of infusion (Day 1 (first dose) and Day 14 (last dose)). Five additional blood draws will be obtained at 10, 12, 24, 36 and 48 hours following the start of infusion of the last dose (morning of Day 14).
Time frame: Day 1 and Day 14